Drug Patents owned by Astrazeneca Ab

1. Drug name - BREZTRI AEROSPHERE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9463161 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems May, 2030

(7 years from now)

US8703806 ASTRAZENECA AB Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents May, 2030

(7 years from now)

US8808713 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems May, 2030

(7 years from now)

US8324266 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents May, 2030

(7 years from now)

US9415009 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents May, 2030

(7 years from now)

US10716753 ASTRAZENECA AB Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems May, 2030

(7 years from now)

US8815258 ASTRAZENECA AB Compositions, methods and systems for respiratory delivery of two or more active agents Mar, 2031

(8 years from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage
Strength Dosage Availability
0.16MG/INH;0.0048MG/INH;0.009MG/INH AEROSOL, METERED;INHALATION Prescription

2. Drug name - BYDUREON

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Oct, 2022

(4 days from now)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Apr, 2023

(6 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Dec, 2025

(3 years from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method Apr, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8758292 ASTRAZENECA AB Administering apparatus with functional drive element Nov, 2027

(5 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Dec, 2027

(5 years from now)

US8216180 ASTRAZENECA AB Administering apparatus with functional drive element Jan, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8439864 ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps Mar, 2028

(5 years from now)

US9320853 ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule Mar, 2028

(5 years from now)

US8758292

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element May, 2028

(5 years from now)

US8216180

(Pediatric)

ASTRAZENECA AB Administering apparatus with functional drive element Jul, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Sep, 2028

(5 years from now)

US9320853

(Pediatric)

ASTRAZENECA AB Method for administering a fluid active substance from a multi-chamber ampoule Sep, 2028

(5 years from now)

US8439864

(Pediatric)

ASTRAZENECA AB Device for administering fluid from a multi-chamber ampoule in incremental steps Sep, 2028

(5 years from now)

US8827963 ASTRAZENECA AB Administering device with holding mechanism Feb, 2029

(6 years from now)

US8690837 ASTRAZENECA AB Mixing device for a two-chamber ampoule May, 2029

(6 years from now)

US8827963

(Pediatric)

ASTRAZENECA AB Administering device with holding mechanism Aug, 2029

(6 years from now)

US8690837

(Pediatric)

ASTRAZENECA AB Mixing device for a two-chamber ampoule Nov, 2029

(7 years from now)

US8998876 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8998876

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder Jul, 2030

(7 years from now)

US8721615

(Pediatric)

ASTRAZENECA AB Ampoule comprising an ampoule holder Jul, 2030

(7 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; Reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin

Dosage: FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/VIAL FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued
2MG FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Discontinued

3. Drug name - BYDUREON BCISE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6824822 ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Oct, 2022

(4 days from now)

US6824822

(Pediatric)

ASTRAZENECA AB Residual solvent extraction method and microparticles produced thereby Apr, 2023

(6 months from now)

US7563871 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US9238076

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US7563871

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2024

(2 years from now)

US7612176 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8461105

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7612176

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US8431685

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Oct, 2025

(3 years from now)

US7456254

(Pediatric)

ASTRAZENECA AB Polymer-based sustained release device Dec, 2025

(3 years from now)

US6515117

(Pediatric)

ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method Apr, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US9884092 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8906851

(Pediatric)

ASTRAZENECA AB Method for treating diabetes Feb, 2027

(4 years from now)

US9884092

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8329648

(Pediatric)

ASTRAZENECA AB Methods for treating diabetes and reducing body weight Feb, 2027

(4 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8501698

(Pediatric)

ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Dec, 2027

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972

(Pediatric)

ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Sep, 2028

(5 years from now)

US8895033 ASTRAZENECA AB Sustained release formulations using non-aqueous carriers Oct, 2030

(8 years from now)

US8895033

(Pediatric)

ASTRAZENECA AB Sustained release formulations using non-aqueous carriers Apr, 2031

(8 years from now)

Drugs and Companies using EXENATIDE SYNTHETIC ingredient

Treatment: As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation as an adjunct to diet and exercise to provide a release profile having a ratio of c-max to c-avg of about 3 or less; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; Improving glycemic control in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; reducing fasting plasma glucose in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; reducing hba1c in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; reducing body weight in adults with type 2 diabetes mellitus by administering an exenatide formulation once weekly as an adjunct to diet and exercise to achieve a mean steady state plasma concentration of exenatide at least 170 pg/ml; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin and metformin; As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with dapagliflozin as add-on to metformin; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with metformin, a sulfonylurea, a thiazolidinedione, or combination of any two of these therapies; stimulating insulin release in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in combination with basal insulin or basal insulin plus metformin; delaying gastric emptying in adults with type 2 diabetes mellitus by administering a pre-mixed exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with metformin and/or sulfonylurea; improving glycemic control in patients 10 years of age and older with type 2 diabetes mellitus by administering a sustained-release exenatide formulation as an adjunct to diet and exercise; as an adjunct to diet and exercise to improve glycemic control in patients 10 to 17 years of age with type 2 diabetes mellitus in combination with insulin alone or insulin plus one other oral antidiabetic medication

Dosage: SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS

More Information on Dosage
Strength Dosage Availability
2MG/0.85ML (2MG/0.85ML) SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS Prescription

4. Drug name - FARXIGA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9238076 ASTRAZENECA AB Polymer-based sustained release device Apr, 2024

(1 year, 6 months from now)

US8431685 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US8461105 ASTRAZENECA AB Polymer-based sustained release device Apr, 2025

(2 years from now)

US7456254 ASTRAZENECA AB Polymer-based sustained release device Jun, 2025

(2 years from now)

US8906851 ASTRAZENECA AB Method for treating diabetes Aug, 2026

(3 years from now)

US8329648 ASTRAZENECA AB Methods for treating diabetes and reducing body weight Aug, 2026

(3 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US7851502 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Aug, 2028

(5 years from now)

US8721615 ASTRAZENECA AB Ampoule comprising an ampoule holder Jan, 2030

(7 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof May, 2030

(7 years from now)

US10973836 ASTRAZENECA AB Methods of treating heart failure with reduced ejection fraction Mar, 2040

(17 years from now)

Drugs and Companies using DAPAGLIFLOZIN ingredient

Treatment: Treatment of type 2 diabetes mellitus in combination with exenatide; Reducing hba1c in a human in need thereof in combination with a sustained-release composition containing exendin-4; treatment of type 2 diabetes mellitus in combination with exenatide; reducing fasting plasma glucose in a human in need thereof in combination with a sustained-release composition containing exendin-4; Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in combination with exenatide; treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone; Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG TABLET;ORAL Prescription
10MG TABLET;ORAL Prescription

5. Drug name - KOMBIGLYZE XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN1698601A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2010

(12 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1213028C ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1427826A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200201154P3 ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN206543B ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1559710A3 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2995615B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP1559710B1 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A2 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2995615A1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A3 ASTRAZENECA AB N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2272825B1 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP1559710A2 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP1261586B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP1261586A2 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

US9339472 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

More Information on Dosage
Strength Dosage Availability
1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription
500MG;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Prescription

6. Drug name - ONGLYZA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN1698601A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2010

(12 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1213028C ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1427826A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200201154P3 ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN206543B ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1559710A3 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2995615B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP1559710B1 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A2 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2995615A1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A3 ASTRAZENECA AB N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2272825B1 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP1559710A2 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP1261586B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP1261586A2 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7951400 ASTRAZENECA AB Coated tablet formulation and method Nov, 2028

(6 years from now)

More Information on Dosage
Strength Dosage Availability
EQ 2.5MG BASE TABLET;ORAL Prescription
EQ 5MG BASE TABLET;ORAL Prescription

7. Drug name - QTERN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN1698601A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2010

(12 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1213028C ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1427826A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200201154P3 ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN206543B ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1559710A3 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2995615B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP1559710B1 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A2 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2995615A1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A3 ASTRAZENECA AB N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2272825B1 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP1559710A2 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP1261586B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP1261586A2 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8361972 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8221786 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

Drugs and Companies using DAPAGLIFLOZIN; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; Treatment of type 2 diabetes mellitus; method for treating type 2 diabetes mellitus (t2dm) in patients who are already treated with dapagliflozin and saxagliptin; method for treating type 2 diabetes mellitus (t2dm) in patients who have inadequate control with dapagliflozin

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
5MG;EQ 5MG BASE TABLET;ORAL Prescription
10MG;EQ 5MG BASE TABLET;ORAL Prescription

8. Drug name - QTERNMET XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44186 ASTRAZENECA AB Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
Jul, 2023

(9 months from now)

US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN1698601A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2010

(12 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1213028C ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1427826A ASTRAZENECA AB Based On Cyclopropyl Fused Pyrrolidine, Dipeptidyl Peptidase Iv Inhibitor, Preparation Method And Use Thereof
Mar, 2021

(1 year, 6 months ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200201154P3 ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN206543B ASTRAZENECA AB A Cyclopropyl-Fused Pyrrolidine-Based Compound
Mar, 2021

(1 year, 6 months ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1559710A3 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2995615B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP1559710B1 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A2 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2995615A1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv And Their Pharmaceutical Use
Mar, 2021

(1 year, 7 months ago)

EP2272825A3 ASTRAZENECA AB N-Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP2272825B1 ASTRAZENECA AB Protected Amino Hydroxy Adamantane Carboxylic Acid And Process For Its Preparation
Mar, 2021

(1 year, 7 months ago)

EP1559710A2 ASTRAZENECA AB Dipeptidyl Peptidase Iv Inhibitors Based On Cyclopropyl-Fused Pyrrolidine, Process For Their Preparation And Their Use
Mar, 2021

(1 year, 7 months ago)

EP1261586B1 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP1261586A2 ASTRAZENECA AB Cyclopropyl-Fused Pyrrolidine-Based Inhibitors Of Dipeptidyl Peptidase Iv, Processes For Their Preparation, And Their Use
Mar, 2026

(3 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8628799 ASTRAZENECA AB Coated tablet formulation and method Jul, 2025

(2 years from now)

US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8716251 ASTRAZENECA AB Pharmaceutical formulations containing an SGLT2 inhibitor Mar, 2028

(5 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations Nov, 2030

(8 years from now)

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE ingredient

Treatment: Treatment of type 2 diabetes mellitus

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 2.5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
5MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued
10MG;1GM;EQ 5MG BASE TABLET, EXTENDED RELEASE;ORAL Discontinued

9. Drug name - XIGDUO XR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US6515117 ASTRAZENECA AB C-aryl glucoside SGLT2 inhibitors and method
Oct, 2025

(3 years from now)

US7919598 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same
Dec, 2029

(7 years from now)

CN1896088A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Jul, 2009

(13 years ago)

CN101092409A ASTRAZENECA AB C-Glucosinolates Sglt2 Inhibitor And Method
May, 2011

(11 years ago)

CN1284793C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1407990A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

CN1653075A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN100534997C ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN102627676A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitor And Method
May, 2023

(7 months from now)

CN101628905A ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN101628905B ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2023

(7 months from now)

CN103319445B ASTRAZENECA AB Crystal Structure Of The Sglt2 Inhibitor And Preparation Method Thereof
Jun, 2027

(4 years from now)

CN101479287A ASTRAZENECA AB Crystalline Solvates And Complexes Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl)Methyl)Phenyl)-D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773B ASTRAZENECA AB Used As Sglt2 Inhibitors For The Treatment Of Diabetes, (1S) -1, 5 - -L-C-(3 - ((Phenyl) Methyl) Phenyl) Crystalline Solvates And Complexes Of -D - Glucitol Derivatives And Amino Acid
Jun, 2027

(4 years from now)

CN101479287B ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103145773A ASTRAZENECA AB Crystalline Solvates And Complexes Of (Is) -1, 5-Anhydro-L-C- (3- ( (Phenyl) Methyl) Phenyl) -D-Glucitol Derivatives With Amino Acids As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

CN103319445A ASTRAZENECA AB Sglt2 Inhibitor Crystal Structure And Its Preparation Method
Jun, 2027

(4 years from now)

IN200200433P3 ASTRAZENECA AB A C-Aryl Glucoside
Oct, 2020

(2 years ago)

IN200700019I3 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
Jan, 2027

(4 years from now)

EP1224195A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP1224195B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors
Oct, 2020

(2 years ago)

EP3045466A1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374B1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP2069374A1 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3045466B1 ASTRAZENECA AB (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol Propylene Glycol Solvate As Sgt2 Inhibitor For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP3363807A1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP3363807B1 ASTRAZENECA AB Pharmaceutical Composition Comprising Crystalline (2S,3R,4S,5S,6R)-2-[4-Chloro-3-(4-Ethoxy-Benzyl)-Phenyl]-6-Hydroxymethyl-2-Methoxy-Tetrahydro-Pyran-3,4,5-Triol (S)-Propylene Glycol Solvate
Jun, 2027

(4 years from now)

EP2069374B2 ASTRAZENECA AB Crystalline Solvates Of (1S)-1,5-Anhydro-1-C-(3-((Phenyl) Methyl) Phenyl)-D-Glucitol Derivatives With Alcohols As Sglt2 Inhibitors For The Treatment Of Diabetes
Jun, 2027

(4 years from now)

EP1506211A4 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211B1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

EP1506211A1 ASTRAZENECA AB C-Aryl Glucoside Sglt2 Inhibitors And Method
May, 2028

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8501698 ASTRAZENECA AB Crystal structures of SGLT2 inhibitors and processes for preparing same Jun, 2027

(4 years from now)

US8685934 ASTRAZENECA AB Methods for treating extreme insulin resistance in patients resistant to previous treatment with other anti-diabetic drugs employing an SGLT2 inhibitor and compositions thereof May, 2030

(7 years from now)

US9616028 ASTRAZENECA AB Bilayer tablet formulations Nov, 2030

(8 years from now)

Drugs and Companies using DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Treatment of type 2 diabetes mellitus; Treatment of type 2 diabetes mellitus in a patient, wherein glycemic control (hba1c < 7.0%) is not achievable using one or more of insulin, metformin, pioglitazone, or rosiglitazone

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
5MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;1GM TABLET, EXTENDED RELEASE;ORAL Prescription
10MG;500MG TABLET, EXTENDED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.